Organon Acquires Forendo Pharma

PharmaEssentia Acquires FORUS Therapeutics to Expand Canadian MPN Footprint

June 11, 2026

Healthcare Services

PharmaEssentia Corporation announced it will acquire 100% of Canadian specialty pharmaceutical company FORUS Therapeutics Inc. in a transaction valued at US$36.5 million. The deal is intended to deepen PharmaEssentia’s presence in Canada’s hematology-oncology myeloproliferative neoplasm (MPN) market and accelerate commercialization of BESREMi (ropeginterferon alfa-2b) by integrating FORUS’s regulatory, medical, and commercial capabilities.

Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

April 26, 2026

Healthcare Services

Sun Pharmaceutical Industries (Sun Pharma) entered into a definitive agreement to acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction valuing Organon at an enterprise value of $11.75 billion. The deal is expected to close in early 2027, subject to customary regulatory approvals and Organon stockholder approval.

Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen

April 1, 2025

Pharmaceuticals

Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.

Symeres Acquires Organix Inc.

April 26, 2022

Biotechnology

Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.

Partners Group Acquires Majority Stake in Forefront Dermatology from OMERS Private Equity

February 10, 2022

Healthcare Services

Partners Group has signed an agreement to acquire OMERS Private Equity's interest in Forefront Dermatology, the largest physician-led dermatology group in the U.S. Forefront's physicians and executive team — and OMERS — will remain minority investors as Partners Group becomes the lead sponsor to support continued geographic expansion and growth; the deal is expected to close in early Q2 2022.

Organon Acquires Alydia Health

June 16, 2021

Medical Devices

Organon completed its acquisition of Alydia Health, a commercial-stage medical device company focused on preventing postpartum hemorrhage, for total consideration of $240 million (including up to $25 million in contingent milestones). The deal expands Organon’s portfolio into medical devices and leverages its global commercial footprint to broaden access to Alydia’s Jada System for maternal hemorrhage worldwide.